Uploaded August 2026 | Updated November 2026, 27 minutes ago
New GLP-1 research is turning up some wild numbers on cancer risk, but almost nobody's mentioning the biggest catch. Juliet and Kelly break down three major studies: a Penn Medicine study of 110,000 women showing a 30% lower breast cancer risk on GLP-1s, a study of 12,000+ cancer patients linking GLP-1 use to slower cancer progression across tumor types, and a third study showing lower overall cancer risk across multiple cancer types.
The catch: all three are observational studies. That means correlation, not proof of cause and effect. Even the researchers behind this data are calling for real double-blind clinical trials before anyone draws conclusions.
Also in this episode: Hiking the Haute Route with the kids on a torn ACL, what Thorne Supplements being acquired by Procter & Gamble means for quality, and Kasia Niewiadoma's historic climb during the Tour de France Femmes.
Watch the full episode here: youtu.be/2gor6BvPhNA
🎧 Subscribe for new episodes of RECESS every other week.
#GLP1 #Ozempic #CancerResearch #RECESSPodcast
About The Ready State:
The Ready State provides athletes, coaches, and humans of all walks of life the tools to relieve pain, prevent injury, and improve physical performance. Subscribe to Mobility Coach for customized mobility coaching, tailored to your body and lifestyle.
👉 Start a 7-day FREE TRIAL today at bit.ly/MC-FreeTrial.
Connect with The Ready State:
Visit the The Ready State WEBSITE: thereadystate.com
Follow The Ready State on INSTAGRAM: instagram.com/thereadystate
Like The Ready State on FACEBOOK: facebook.com/thereadystate
Follow The Ready State on TWITTER: twitter.com/thereadystate
Follow The Ready State on TIKTOK: tiktok.com/@the_readystate
New GLP-1 research is turning up some wild numbers on cancer risk, but almost nobody's mentioning the biggest catch. Juliet and Kelly break down three major studies: a Penn Medicine study of 110,000 women showing a 30% lower breast cancer risk on GLP-1s, a study of 12,000+ cancer patients linking GLP-1 use to slower cancer progression across tumor types, and a third study showing lower overall cancer risk across multiple cancer types.
The catch: all three are observational studies. That means correlation, not proof of cause and effect. Even the researchers behind this data are calling for real double-blind clinical trials before anyone draws conclusions.
Also in this episode: Hiking the Haute Route with the kids on a torn ACL, what Thorne Supplements being acquired by Procter & Gamble means for quality, and Kasia Niewiadoma's historic climb during the Tour de France Femmes.
Watch the full episode here: youtu.be/2gor6BvPhNA
🎧 Subscribe for new episodes of RECESS every other week.
#GLP1 #Ozempic #CancerResearch #RECESSPodcast
About The Ready State:
The Ready State provides athletes, coaches, and humans of all walks of life the tools to relieve pain, prevent injury, and improve physical performance. Subscribe to Mobility Coach for customized mobility coaching, tailored to your body and lifestyle.
👉 Start a 7-day FREE TRIAL today at bit.ly/MC-FreeTrial.
Connect with The Ready State:
Visit the The Ready State WEBSITE: thereadystate.com
Follow The Ready State on INSTAGRAM: instagram.com/thereadystate
Like The Ready State on FACEBOOK: facebook.com/thereadystate
Follow The Ready State on TWITTER: twitter.com/thereadystate
Follow The Ready State on TIKTOK: tiktok.com/@the_readystate










